<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37851721</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1678-8060</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Memorias do Instituto Oswaldo Cruz</Title><ISOAbbreviation>Mem Inst Oswaldo Cruz</ISOAbbreviation></Journal><ArticleTitle>Long COVID-19 syndrome associated with Omicron XBB.1.5 infection: a case report.</ArticleTitle><Pagination><StartPage>e230069</StartPage><MedlinePgn>e230069</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e230069</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/0074-02760230069</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0074-02762023000101125</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is interest in lingering non-specific symptoms after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, referred to as Long coronavirus disease 2019 (Long COVID-19). It remains unknown whether the risk of Long COVID-19 is associated with pre-existing comorbidities or initial COVID-19 severity, including infections due to new Omicron lineages which predominated in 2023.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this case report was to characterize the clinical features of acute XBB.1.5 infection followed by Long COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We followed a 73-year old female resident of Rio de Janeiro with laboratory-confirmed SARS-CoV-2 during acute infection and subsequent months. The SARS-CoV-2 lineage was determined by genome sequencing.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The participant denied comorbidities and had completed a two-dose vaccination schedule followed by two booster doses eight months prior to SARS-CoV-2 infection. Primary infection by viral lineage XBB.1.5. was clinically mild, but the participant subsequently reported persistent fatigue.</AbstractText><AbstractText Label="MAIN CONCLUSIONS" NlmCategory="CONCLUSIONS">This case demonstrates that Long COVID-19 may develop even after mild disease due to SARS-CoV-2 in fully vaccinated and boosted individuals without comorbidities. Continued monitoring of new SARS-CoV-2 lineages and associated clinical outcomes is warranted. Measures to prevent infection should continue to be implemented including development of new vaccines and antivirals effective against novel variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esp&#xed;ndola</LastName><ForeName>Ot&#xe1;vio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resende</LastName><ForeName>Paola C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laborat&#xf3;rio de V&#xed;rus Respirat&#xf3;rios e do Sarampo, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guaraldo</LastName><ForeName>Lusiele</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvet</LastName><ForeName>Guilherme Amaral</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuller</LastName><ForeName>Trevon L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>University of California Los Angeles, Institute of the Environment and Sustainability, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penetra</LastName><ForeName>Stephanie Lema Suarez</ForeName><Initials>SLS</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Heloisa Ferreira Pinto</ForeName><Initials>HFP</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pina-Costa</LastName><ForeName>Anielle</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Michele Fernanda Borges</ForeName><Initials>MFB</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moraes</LastName><ForeName>Isabella Campos Vargas</ForeName><Initials>ICV</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medeiros</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitworth</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, Department of Clinical Research, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, Department of Clinical Research, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nagasaki University, School of Tropical Medicine and Global Health, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen-Saines</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of California Los Angeles, David Geffen School of Medicine, Division of Pediatric Infectious Diseases, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siqueira</LastName><ForeName>Marilda M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laborat&#xf3;rio de V&#xed;rus Respirat&#xf3;rios e do Sarampo, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brasil</LastName><ForeName>Patr&#xed;cia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9555-7976</Identifier><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Doen&#xe7;as Febris Agudas, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/V033530/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AI140718</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI172252</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Mem Inst Oswaldo Cruz</MedlineTA><NlmUniqueID>7502619</NlmUniqueID><ISSNLinking>0074-0276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37851721</ArticleId><ArticleId IdType="pmc">PMC10581372</ArticleId><ArticleId IdType="doi">10.1590/0074-02760230069</ArticleId><ArticleId IdType="pii">S0074-02762023000101125</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ma KC, Shirk P, Lambrou AS, Hassell N, Zheng XY, Payne AB. Genomic surveillance for SARS-CoV-2 variants circulation of Omicron lineages - United States, January 2022-May 2023. MMWR-Morbid Mortal. 2023;72:651&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10328465</ArticleId><ArticleId IdType="pubmed">37319011</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control  2023. https://www.ecdc.europa.eu/en/covid-19/country-overviews</Citation></Reference><Reference><Citation>Yue C, Song WL, Wang L, Jian FC, Chen XS, Gao F. ACE2 binding and antibody evasion in enhanced transmissibility of XBB 1.5. Lancet Infect Dis. 2023;23:278&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9897732</ArticleId><ArticleId IdType="pubmed">36746173</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Human Services.Office of the Assistant Secretary for Health . National Research Action Plan on Long COVID. Washington: DC, Department of Health and Human Services; 2022.</Citation></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of COVID-19 summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136&#x2013;n136.</Citation><ArticleIdList><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA. Development of a definition of postacute sequelae of SARS-CoV-2 infection. Jama. 2023;329:1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B, Harrer T, Mardin C, Kruse F, Hoffmanns J, Rogge L. Case report neutralization of autoantibodies targeting G-protein-coupled receptors improves capillary impairment and fatigue symptoms after COVID-19 infection. Front Med. 2021;8:754667&#x2013;754667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8637609</ArticleId><ArticleId IdType="pubmed">34869451</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu PK, Faraone JN, Evans JP, Zheng YM, Carlin C, Anghelina M. Enhanced evasion of neutralizing antibody response by Omicron XBB 1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 2023;42:112443&#x2013;112443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10279473</ArticleId><ArticleId IdType="pubmed">37104089</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein EY, Fall A, Norton JM, Eldesouki RE, Abdullah O, Han LJ. Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysis. J Clin Virol. 2023;165:105500&#x2013;105500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10232717</ArticleId><ArticleId IdType="pubmed">37290254</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>